Type 17 CD8+ T cells display enhanced antitumor immunity
Open Access
- 16 July 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 114 (3) , 596-599
- https://doi.org/10.1182/blood-2009-02-203935
Abstract
Interleukin-17 (IL-17)–secreting CD8+ T cells have been described, but they have not been thoroughly studied and they do not have a known role in canKeywords
This publication has 24 references indexed in Scilit:
- Cutting Edge: IFN-γ Enables APC to Promote Memory Th17 and Abate Th1 Cell DevelopmentThe Journal of Immunology, 2008
- The Clone Ranger?Molecular Therapy, 2008
- Th17 and cancer: friends or foes?Blood, 2008
- Less Yin, More Yang: Confronting the Barriers to Cancer ImmunotherapyClinical Cancer Research, 2007
- Induction of a distinct CD8 Tnc17 subset by transforming growth factor-β and interleukin-6Journal of Leukocyte Biology, 2007
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper CellsCell, 2006
- Effector and memory CD8+ T cell fate coupled by T-bet and eomesoderminNature Immunology, 2005
- Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cellsJournal of Clinical Investigation, 2005
- Control of Effector CD8 + T Cell Function by the Transcription Factor EomesoderminScience, 2003